Caution in Biological Staging of Parkinson's Disease

The notion of biological staging in Parkinson's disease is gaining attention due to the emergence of biomarkers, particularly related to alpha-synuclein. However, experts caution that rushing to establish these definitions may lead to unintended consequences, similar to challenges faced in oncology and Alzheimer's research. The message emphasizes the need for a measured approach, suggesting that while excitement about advancements is warranted, the field should allow sufficient time for evolution and understanding. By taking a cautious stance, better dialogue and strategies can emerge that responsibly incorporate the latest findings in the classification of this complex disease.